Xalkori (crizotinib) Capsules, for Oral Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)   April 2016 ADVERSE REACTIONS Clinical Trials Experience Renal impairment The estimated glomerular filtration...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts